Sanofi (NASDAQ:SNY) Receives Average Rating of “Buy” from Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned an average recommendation of “Buy” from the five analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $62.50.

A number of equities analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Price Performance

Sanofi stock opened at $55.45 on Friday. The stock’s 50 day moving average price is $54.84 and its two-hundred day moving average price is $52.82. The stock has a market capitalization of $140.72 billion, a price-to-earnings ratio of 22.27, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several large investors have recently modified their holdings of SNY. Abel Hall LLC lifted its holdings in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after buying an additional 194 shares in the last quarter. Providence Capital Advisors LLC increased its holdings in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after purchasing an additional 201 shares during the period. Keudell Morrison Wealth Management boosted its stake in Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after buying an additional 217 shares during the period. Bailard Inc. grew its position in Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after buying an additional 220 shares in the last quarter. Finally, Old Port Advisors increased its stake in Sanofi by 0.6% in the 4th quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after acquiring an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.